Masitinib Evidence: Trial Results and Peer-Reviewed Publications
Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:
The clinical evidence base for Masitinib comprises 15 peer-reviewed publications across 12 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Mastocytosis, Alzheimer Disease, Multiple Sclerosis, Chronic Progressive, and Arthritis, Rheumatoid. Most recent publication: MasitinibL shows promise as a drug-like analog of masitinib that elicits comparable SARS-Cov-2 3CLpro inhibition with low kinase preference., Sci Rep, 2023.
Top peer-reviewed publications
Curated set of pivotal-trial result papers and recent publications in high-tier journals.
- Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.Vermersch P, Benrabah R, Schmidt N, et al. · BMC Neurol · 2013
- Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.Tebib J, Mariette X, Bourgeois P, et al. · Arthritis Res Ther · 2010
- Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.Piette F, Belmin J, Vincent H, et al. · Alzheimers Res Ther · 2012
- Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.Paul C, Sans B, Suarez F, et al. · Am J Hematol · 2010
- Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.Lortholary O, Chandesris MO, Bulai Livideanu C, et al. · Lancet · 2018
- Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).Le Cesne A, Blay JY, Bui BN, et al. · Eur J Cancer · 2010
- A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.Deplanque G, Demarchi M, Hebbar M, et al. · Ann Oncol · 2016
- Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.Adenis A, Blay JY, Bui-Nguyen B, et al. · Ann Oncol · 2015
Publications by year
2010–2023: 15 publications.
2010
3
2012
1
2013
1
2015
1
2016
1
2017
1
2018
1
2021
1
2022
3
2023
2
Publications by indication
Mastocytosis (4)
- Cytochromes P450 2C8 and 3A Catalyze the Metabolic Activation of the Tyrosine Kinase Inhibitor Masitinib.
- Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.
- A new therapeutic advance for symptomatic systemic mastocytosis?
- Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.
Alzheimer Disease (3)
- Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial.
- Effects of Chronic Masitinib Treatment in APPswe/PSEN1dE9 Transgenic Mice Modeling Alzheimer's Disease.
- Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.
Multiple Sclerosis, Chronic Progressive (2)
- Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.
- Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.
Arthritis, Rheumatoid (1)
- Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.
Pancreatic Neoplasms (1)
- A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.
Amyotrophic Lateral Sclerosis (1)
- Long-term survival analysis of masitinib in amyotrophic lateral sclerosis.
Publications by journal
- Alzheimers Res Ther2 papers
- Lancet2 papers
- Ann Oncol2 papers
- BMC Neurol1 paper
- Arthritis Res Ther1 paper
- Am J Hematol1 paper
- Eur J Cancer1 paper
- Neurol Neuroimmunol Neuroinflamm1 paper
- Ther Adv Neurol Disord1 paper
- Chem Res Toxicol1 paper
All Masitinib publications (15)
2023 (2 papers)
- MasitinibL shows promise as a drug-like analog of masitinib that elicits comparable SARS-Cov-2 3CLpro inhibition with low kinase preference.Durojaye OA, Okoro NO, Odiba AS, et al. · Sci Rep · 2023 · Derived
- Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial.Dubois B, López-Arrieta J, Lipschitz S, et al. · Alzheimers Res Ther · 2023 · Derived
2022 (3 papers)
- Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.Vermersch P, Brieva-Ruiz L, Fox RJ, et al. · Neurol Neuroimmunol Neuroinflamm · 2022 · Derived
- Long-term survival analysis of masitinib in amyotrophic lateral sclerosis.Mora JS, Bradley WG, Chaverri D, et al. · Ther Adv Neurol Disord · 2022 · Derived
- Cytochromes P450 2C8 and 3A Catalyze the Metabolic Activation of the Tyrosine Kinase Inhibitor Masitinib.Latham BD, Oskin DS, Crouch RD, et al. · Chem Res Toxicol · 2022 · Derived
2021 (1 paper)
- Effects of Chronic Masitinib Treatment in APPswe/PSEN1dE9 Transgenic Mice Modeling Alzheimer's Disease.Li T, Martin E, Abada YS, et al. · J Alzheimers Dis · 2021 · Background
2018 (1 paper)
- Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.Lortholary O, Chandesris MO, Bulai Livideanu C, et al. · Lancet · 2018 · Trial result
2017 (1 paper)
- A new therapeutic advance for symptomatic systemic mastocytosis?Arock M · Lancet · 2017 · Background
2016 (1 paper)
- A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.Deplanque G, Demarchi M, Hebbar M, et al. · Ann Oncol · 2016 · Trial result
2015 (1 paper)
- Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.Adenis A, Blay JY, Bui-Nguyen B, et al. · Ann Oncol · 2015 · Trial result
2013 (1 paper)
- Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.Vermersch P, Benrabah R, Schmidt N, et al. · BMC Neurol · 2013 · Trial result
2012 (1 paper)
- Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.Piette F, Belmin J, Vincent H, et al. · Alzheimers Res Ther · 2012 · Trial result
2010 (3 papers)
- Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.Tebib J, Mariette X, Bourgeois P, et al. · Arthritis Res Ther · 2010 · Trial result
- Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.Paul C, Sans B, Suarez F, et al. · Am J Hematol · 2010 · Trial result
- Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).Le Cesne A, Blay JY, Bui BN, et al. · Eur J Cancer · 2010 · Trial result
Sources and methodology
- Publications:
ctgov.study_references(PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference typesRESULT,DERIVED, andBACKGROUND. - Per-arm outcome values:
ctgov.outcome_measurementsjoined toctgov.design_outcomeswhereoutcome_type = 'PRIMARY', restricted to phasePHASE3andPHASE2/PHASE3. - Publication metadata (title, journal, year, authors): PubMed E-utilities
efetch.fcgi - Data freshness: Thu, 14 May 2026 21:55:22 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).